Six major 2025 sepsis/septic shock trials, summarized in full CCR 11-part format — spanning precision immunotherapy, personalized hemodynamic resuscitation, adjunctive glucocorticoids, tissue-perfusion targets, and two negative adjunctive-agent trials.
ImmunoSep — Precision Immunotherapy to Improve Sepsis OutcomesANDROMEDA-SHOCK-2 — Personalized Hemodynamic Resuscitation Targeting CRTSONIA — Pragmatic Trial of Glucocorticoids for CAP (Kenya)TARTARE-2S — Targeted Tissue Perfusion vs Macrocirculatory-Guided CareTESTS — Thymosin α1 for SepsisTongyoo et al. — Adjunctive Terlipressin in Refractory Septic Shock🪠